Literature DB >> 20962864

Therapy: What evidence should guide the use of thiazolidinediones?

Matthew C Riddle1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20962864     DOI： 10.1038/nrendo.2010.156

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

Review 1.  Thiazolidinediones.

Authors:  Hannele Yki-Järvinen
Journal:  N Engl J Med       Date:  2004-09-09       Impact factor: 91.245

2.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

3.  Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.

Authors:  David J Graham; Rita Ouellet-Hellstrom; Thomas E MaCurdy; Farzana Ali; Christopher Sholley; Christopher Worrall; Jeffrey A Kelman
Journal:  JAMA       Date:  2010-06-28       Impact factor: 56.272

Review 4.  Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

Authors:  Steven E Nissen; Kathy Wolski
Journal:  Arch Intern Med       Date:  2010-07-26

5.  Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.

Authors:  Yoon K Loke; Sonal Singh; Curt D Furberg
Journal:  CMAJ       Date:  2008-12-10       Impact factor: 8.262

6.  Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.

Authors:  Edoardo Mannucci; Matteo Monami; Mauro Di Bari; Caterina Lamanna; Francesca Gori; Gian Franco Gensini; Niccolò Marchionni
Journal:  Int J Cardiol       Date:  2009-03-27       Impact factor: 4.164

7.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

8.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Authors:  Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal:  Lancet       Date:  2009-06-06       Impact factor: 79.321

9.  A randomized trial of therapies for type 2 diabetes and coronary artery disease.

Authors:  Robert L Frye; Phyllis August; Maria Mori Brooks; Regina M Hardison; Sheryl F Kelsey; Joan M MacGregor; Trevor J Orchard; Bernard R Chaitman; Saul M Genuth; Suzanne H Goldberg; Mark A Hlatky; Teresa L Z Jones; Mark E Molitch; Richard W Nesto; Edward Y Sako; Burton E Sobel
Journal:  N Engl J Med       Date:  2009-06-07       Impact factor: 91.245

10.  Thiazolidinediones and heart failure: a teleo-analysis.

Authors:  Sonal Singh; Yoon K Loke; Curt D Furberg
Journal:  Diabetes Care       Date:  2007-05-29       Impact factor: 19.112
  10 in total
  1 in total

1.  PPARγ antagonist attenuates mouse immune-mediated bone marrow failure by inhibition of T cell function.

Authors:  Kazuya Sato; Xingmin Feng; Jichun Chen; Jungang Li; Pawel Muranski; Marie J Desierto; Keyvan Keyvanfar; Daniela Malide; Sachiko Kajigaya; Neal S Young
Journal:  Haematologica       Date:  2015-11-20       Impact factor: 9.941
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.